Gene Therapies for Heart Failure Gain Momentum After Period of Stagnation

Resurgence in Cardiac Gene Therapy

Gene therapies designed to treat and repair failing hearts are experiencing a resurgence after several years of limited progress. While the field previously entered a period of stagnation, new developments in delivery mechanisms and genetic targeting are bringing these treatments back to the forefront of cardiovascular medicine.

Researchers are focusing on shifting from temporary treatments to durable, long-term solutions for heart failure. This shift is driven by an effort to address the underlying genetic causes of cardiac dysfunction rather than merely managing symptoms through traditional pharmacological means.

Targeting Cholesterol and Heart Disease

Parallel to efforts in heart failure, significant progress has been made in gene therapies targeting cholesterol, a primary contributor to heart disease. A study conducted by Verve Therapeutics—a company owned by Eli Lilly Co.—and published May 25 in the New England Journal of Medicine, detailed a one-time gene therapy that targets the PCSK9 gene.

In a small Phase I trial involving 35 participants, this experimental treatment reduced LDL cholesterol levels by between 9% and 62%, depending on the dosage administered. Riyaz S. Patel, a cardiologist at Barts Health NHS Trust and professor of cardiology at University College London, stated that early data provides "encouraging evidence" that in vivo base editing of PCSK9 could offer a novel way to achieve substantial and durable LDL-C reduction with a single treatment.

Patel noted that many patients struggle to maintain cholesterol control using existing medications, which leaves them at significant risk for cardiovascular events. Given that coronary artery disease remains one of the leading causes of death globally, there is a critical need for these types of durable interventions.

Challenges in Delivery and Implementation

Despite recent gains, the path to widespread clinical use remains complex. Developers face significant scientific hurdles, including the need for delivery systems that can accurately reach specific tissues and achieve sufficient expression or editing without triggering adverse immune responses.

Beyond the biological challenges, durability—the ability of the therapy to remain effective over a long period—remains a primary concern for researchers. Additionally, generating meaningful clinical evidence is difficult because many genetic conditions affect very small populations, making large-scale trials challenging to conduct.

Industry perspectives suggest that the next phase of success in cell and gene therapy will depend not only on scientific breakthroughs but also on improvements in clinical operations to bridge the gap between laboratory development and patient delivery.